Clinical Trial Update: Extension Study to Gather Data on Effect of Macugen on the Corneal Endothelium [Phase 4]

View source ↗

Summary

A Phase 4 extension study assessing the effect of Macugen on the corneal endothelium has completed, with results posted in 2020.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Age-related Macular Degeneration
• Diabetic Macular Edema
• Retinal Vein Occlusion

Drugs mentioned

• Macugen (pegaptanib sodium)

Snippet

Sponsor: Bausch & Lomb Incorporated | Conditions: Age-Related Macular Degeneration, Retinal Vein Occlusion | Phase 4 | Status: COMPLETED | Results posted: 2020-10-14